Inhibikase Therapeutics (IKT) Interest Expenses (2020 - 2025)

Inhibikase Therapeutics (IKT) has 6 years of Interest Expenses data on file, last reported at $7.7 million in Q4 2025.

• On a quarterly basis, Interest Expenses changed N/A year-over-year to $7.7 million in Q4 2025; TTM through Dec 2025 was $7.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $31.7 million, up 1.8% from the prior year.
• Interest Expenses for Q4 2025 stood at $7.7 million, up from $38322.0 in the prior quarter.
• Over the last five years, Interest Expenses for IKT reached as high as $7.7 million in Q4 2025 and fell as low as -$18617.0 in Q4 2021.
• Historically, Interest Expenses has averaged $553153.5 across 5 years, with a median of $32275.0 in 2023.
• Across the five-year window, Interest Expenses slumped 360.78% in 2021 and jumped 44675.8% in 2022, its largest moves.
• Year by year, Interest Expenses stood at -$18617.0 in 2021, then surged by 477.6% to $70298.0 in 2022, then slumped by 54.09% to $32275.0 in 2023, then surged by 374.94% to $153288.0 in 2024, then soared by 4923.22% to $7.7 million in 2025.
• Per Business Quant data, the three most recent Interest Expenses figures were $7.7 million in Q4 2025, $38322.0 in Q2 2025, and $1872.0 in Q1 2025.